Page last updated: 2024-11-06

teleocidin b-4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Teleocidin B-4 is a potent tumor promoter and a potent activator of protein kinase C (PKC). It is a cyclic peptide produced by the fungus Streptomyces . Teleocidin B-4 has been studied extensively as a tool for understanding the role of PKC in cell signaling and cancer. Teleocidin B-4 has been shown to promote the growth of tumors in animal models. It has also been shown to induce cell death in some cancer cell lines. The mechanism of action of teleocidin B-4 is thought to be through its ability to bind to and activate PKC. This activation leads to a cascade of events that ultimately results in cell growth or death. The structure of teleocidin B-4 was elucidated in 1981 and its synthesis was achieved in 1986. Teleocidin B-4 has been studied for its potential as an anticancer drug. However, it has not been approved for use in humans. There is interest in its use as a research tool and for further development as a drug candidate.'

teleocidins: structure; RN given refers to teleocidin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72425
CHEMBL ID417692
SCHEMBL ID1278740
MeSH IDM0077899

Synonyms (32)

Synonym
teleocidin
78474-55-2
13-ethenyl-1,3,4,5,7,8,10,11,12,13-decahydro-4-(hydroxymethyl)-8,10,13-trimethyl-7,10-bis(1-methylethyl)-6h-benzo[g]diazonino[7,6,5-cd]indol-6-one
hydroxymethyl-diisopropyl-trimethyl-vinyl-[?]one
brn 4726267
11032-05-6
teleocidin b-4
ccris 8008
teleocidin b4
CHEMBL417692 ,
bdbm50064089
4-hydroxymethyl-7,10-diisopropyl-8,10,13-trimethyl-13-vinyl-(4s,7s,10r,13r)-3,4,5,6,7,8,10,11,12,13-decahydro-1h-benzo[g][1,4]diazonino[7,6,5-cd]indol-6-one
telocidinb-4 4-hydroxymethyl-7,10-diisopropyl-8,10,13-trimethyl-13-vinyl-(4s,7s,10r,13r)-3,4,5,6,7,8,10,11,12,13-decahydro-1h-benzo[g][1,4]diazonino[7,6,5-cd]indol-6-one
olivoretin d
27974yj83l ,
ccris 713
6h-benzo(g)(1,4)diazonino(7,6,5-cd)indol-6-one, 13-ethenyl-1,3,4,5,7,8,10,11,12,13-decahydro-4-(hydroxymethyl)-8,10,13-trimethyl-7,10-bis(1-methylethyl)-, (4s-(4r*,7r*,10s*,13s*))-
unii-27974yj83l
teleocidins
unii-633532z10m
olivoretine d
633532z10m ,
teleocidin b4 [mi]
teleocidin b 4
6h-benzo(g)(1,4)diazonino(7,6,5-cd)indol-6-one, 13-ethenyl-1,3,4,5,7,8,10,11,12,13-decahydro-4-(hydroxymethyl)-8,10,13-trimethyl-7,10-bis(1-methylethyl)-, (4s,7s,10r,13r)-
SCHEMBL1278740
13-ethenyl-4-(hydroxymethyl)-8,10,13-trimethyl-7,10-di(propan-2-yl)-3,4,7,8,10,11,12,13-octahydro-1h-benzo[g][1,4]diazonino[7,6,5-cd]indol-6-ol
DTXSID40911580
Q27263555
(6s,9s,14r,17r)-17-ethenyl-6-(hydroxymethyl)-10,14,17-trimethyl-9,14-di(propan-2-yl)-2,7,10-triazatetracyclo[9.7.1.04,19.013,18]nonadeca-1(18),3,11(19),12-tetraen-8-one
teleocidinb-4
PD119408

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Further, dose-response studies showed that sodium fluoride (NaF), activator of G-binding proteins, and ouabain, inhibitor of Na+/H+ pump, increased levels of IL-6 mRNA."( Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation.
Adelman, DC; Akashi, M; Koeffler, HP; Loussararian, AH; Saito, M, 1990
)
0.28
" The dose-response curves of these two compounds were, in general, similar to that of 12-O-tetradecanoyl-phorbol-13-acetate, a powerful mouse skin tumor promoter."( Inhibition of intercellular communication in Chinese hamster V79 cells by teleocidin.
Chang, C; Fujiki, H; Jone, CM; Sugimura, T; Trosko, JE, 1982
)
0.26
" The high dosage of morphine required to induce anticarcinogenic effects is also discussed."( Anti-cancer effects of morphine through inhibition of tumour necrosis factor-alpha release and mRNA expression.
Fujiki, H; Okabe, S; Sueoka, E; Sueoka, N, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein kinase C delta typeHomo sapiens (human)Ki0.00030.00030.94896.9600AID163528
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
protein phosphorylationProtein kinase C delta typeHomo sapiens (human)
apoptotic processProtein kinase C delta typeHomo sapiens (human)
DNA damage responseProtein kinase C delta typeHomo sapiens (human)
signal transductionProtein kinase C delta typeHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressProtein kinase C delta typeHomo sapiens (human)
regulation of signaling receptor activityProtein kinase C delta typeHomo sapiens (human)
immunoglobulin mediated immune responseProtein kinase C delta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C delta typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C delta typeHomo sapiens (human)
termination of signal transductionProtein kinase C delta typeHomo sapiens (human)
negative regulation of actin filament polymerizationProtein kinase C delta typeHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityProtein kinase C delta typeHomo sapiens (human)
negative regulation of protein bindingProtein kinase C delta typeHomo sapiens (human)
activation of protein kinase activityProtein kinase C delta typeHomo sapiens (human)
positive regulation of superoxide anion generationProtein kinase C delta typeHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C delta typeHomo sapiens (human)
cellular response to UVProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein dephosphorylationProtein kinase C delta typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C delta typeHomo sapiens (human)
B cell proliferationProtein kinase C delta typeHomo sapiens (human)
neutrophil activationProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein import into nucleusProtein kinase C delta typeHomo sapiens (human)
defense response to bacteriumProtein kinase C delta typeHomo sapiens (human)
negative regulation of MAP kinase activityProtein kinase C delta typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C delta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C delta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C delta typeHomo sapiens (human)
negative regulation of inflammatory responseProtein kinase C delta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C delta typeHomo sapiens (human)
protein stabilizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of filopodium assemblyProtein kinase C delta typeHomo sapiens (human)
cell chemotaxisProtein kinase C delta typeHomo sapiens (human)
cellular response to hydrogen peroxideProtein kinase C delta typeHomo sapiens (human)
cellular response to hydroperoxideProtein kinase C delta typeHomo sapiens (human)
negative regulation of platelet aggregationProtein kinase C delta typeHomo sapiens (human)
cellular senescenceProtein kinase C delta typeHomo sapiens (human)
positive regulation of phospholipid scramblase activityProtein kinase C delta typeHomo sapiens (human)
cellular response to angiotensinProtein kinase C delta typeHomo sapiens (human)
regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of glucosylceramide catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of sphingomyelin catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProtein kinase C delta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C delta typeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
protein kinase activityProtein kinase C delta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein bindingProtein kinase C delta typeHomo sapiens (human)
ATP bindingProtein kinase C delta typeHomo sapiens (human)
enzyme activator activityProtein kinase C delta typeHomo sapiens (human)
enzyme bindingProtein kinase C delta typeHomo sapiens (human)
protein kinase bindingProtein kinase C delta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C delta typeHomo sapiens (human)
metal ion bindingProtein kinase C delta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C delta typeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionProtein kinase C delta typeHomo sapiens (human)
nucleusProtein kinase C delta typeHomo sapiens (human)
nucleoplasmProtein kinase C delta typeHomo sapiens (human)
cytoplasmProtein kinase C delta typeHomo sapiens (human)
mitochondrionProtein kinase C delta typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C delta typeHomo sapiens (human)
cytosolProtein kinase C delta typeHomo sapiens (human)
plasma membraneProtein kinase C delta typeHomo sapiens (human)
cell-cell junctionProtein kinase C delta typeHomo sapiens (human)
nuclear matrixProtein kinase C delta typeHomo sapiens (human)
azurophil granule lumenProtein kinase C delta typeHomo sapiens (human)
endolysosomeProtein kinase C delta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C delta typeHomo sapiens (human)
extracellular exosomeProtein kinase C delta typeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID163528Displacement of [3H]PDBu from recombinant Protein kinase C delta1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase Cdelta by synthesis of hydrophobically modified, teleocidin-mimicking benzolactams and computational docking simulation.
AID332395Tumor promoter activity in human HeLa cells assessed as enhancement of incorporation of 32Pi into phospholipid per mg of protein at 0.1 uM1994Journal of natural products, Mar, Volume: 57, Issue:3
New teleocidin-related metabolites, (-)-7-geranylindolactam V and blastmycetin F, from Streptoverticillium blastmyceticum.
AID332393Tumor promoter activity in human HeLa cells assessed as enhancement of incorporation of 32Pi into phospholipid per mg of protein at 1 nM1994Journal of natural products, Mar, Volume: 57, Issue:3
New teleocidin-related metabolites, (-)-7-geranylindolactam V and blastmycetin F, from Streptoverticillium blastmyceticum.
AID81280Effective concentration against monocytes of HL-60 cells growth inhibition1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase Cdelta by synthesis of hydrophobically modified, teleocidin-mimicking benzolactams and computational docking simulation.
AID332391Displacement of [3H]TPA from phorbol ester receptor in ICR mouse epidermal particulate1994Journal of natural products, Mar, Volume: 57, Issue:3
New teleocidin-related metabolites, (-)-7-geranylindolactam V and blastmycetin F, from Streptoverticillium blastmyceticum.
AID332392Tumor promoter activity in human HeLa cells assessed as enhancement of incorporation of 32Pi into phospholipid per mg of protein at 0.1 nM1994Journal of natural products, Mar, Volume: 57, Issue:3
New teleocidin-related metabolites, (-)-7-geranylindolactam V and blastmycetin F, from Streptoverticillium blastmyceticum.
AID332394Tumor promoter activity in human HeLa cells assessed as enhancement of incorporation of 32Pi into phospholipid per mg of protein at 10 nM1994Journal of natural products, Mar, Volume: 57, Issue:3
New teleocidin-related metabolites, (-)-7-geranylindolactam V and blastmycetin F, from Streptoverticillium blastmyceticum.
AID82174Dose inducing HL-60 cell adhesion related to skin tumor promotion.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Active conformation of a tumor promoter, teleocidin. A molecular dynamics study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (226)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990160 (70.80)18.7374
1990's43 (19.03)18.2507
2000's6 (2.65)29.6817
2010's9 (3.98)24.3611
2020's8 (3.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.21 (24.57)
Research Supply Index5.44 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews17 (7.42%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other212 (92.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]